Monoclonal antibodies are widely used for the treatment of infectious human diseases,
including COVID-19. Since the start of the pandemic, eight monoclonal antibodies against …

Treatment with neutralizing monoclonal antibodies (mAbs) against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) contributes to COVID-19 management …

Vaccination and administration of monoclonal antibody cocktails are effective tools to control
the progression of infectious diseases and to terminate pandemics such as COVID-19 …

The use of therapeutic neutralizing antibodies against SARS-CoV-2 infection has been
highly effective. However, there remain few practical antibodies against viruses that are …

Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute
respiratory syndrome-coronavirus-2 (SARS-CoV-2) has led to over 760 million cases and> …

Despite the recent availability of vaccines against severe acute respiratory syndrome
coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 …

Countermeasures to prevent and treat coronavirus disease 2019 (COVID-19) are a global
health priority. We enrolled a cohort of severe acute respiratory syndrome coronavirus 2 …

Background Neutralizing antibodies are approved drugs to treat coronavirus disease-2019
(COVID-19) patients, yet mutations in severe acute respiratory syndrome coronavirus (SARS …

Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, several variants
of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged and …

Human monoclonal antibody (mAb) treatments are promising for COVID-19 prevention, post-
exposure prophylaxis, or therapy. However, the titer of neutralizing antibodies required for …